171 related articles for article (PubMed ID: 28377405)
1. The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression.
Becchetti A; Crescioli S; Zanieri F; Petroni G; Mercatelli R; Coppola S; Gasparoli L; D'Amico M; Pillozzi S; Crociani O; Stefanini M; Fiore A; Carraresi L; Morello V; Manoli S; Brizzi MF; Ricci D; Rinaldi M; Masi A; Schmidt T; Quercioli F; Defilippi P; Arcangeli A
Sci Signal; 2017 Apr; 10(473):. PubMed ID: 28377405
[TBL] [Abstract][Full Text] [Related]
2. Physical and functional interaction between integrins and hERG1 channels in cancer cells.
Pillozzi S; Arcangeli A
Adv Exp Med Biol; 2010; 674():55-67. PubMed ID: 20549940
[TBL] [Abstract][Full Text] [Related]
3. Integrins regulate hERG1 dynamics by girdin-dependent Gαi3: signaling and modeling in cancer cells.
Duranti C; Iorio J; Bagni G; Chioccioli Altadonna G; Fillion T; Lulli M; D'Alessandro FN; Montalbano A; Lastraioli E; Fanelli D; Coppola S; Schmidt T; Piazza F; Becchetti A; Arcangeli A
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37923359
[TBL] [Abstract][Full Text] [Related]
4. hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer.
Crociani O; Zanieri F; Pillozzi S; Lastraioli E; Stefanini M; Fiore A; Fortunato A; D'Amico M; Masselli M; De Lorenzo E; Gasparoli L; Chiu M; Bussolati O; Becchetti A; Arcangeli A
Sci Rep; 2013 Nov; 3():3308. PubMed ID: 24270902
[TBL] [Abstract][Full Text] [Related]
5. Human ether-a-go-go-related gene 1 channels are physically linked to beta1 integrins and modulate adhesion-dependent signaling.
Cherubini A; Hofmann G; Pillozzi S; Guasti L; Crociani O; Cilia E; Di Stefano P; Degani S; Balzi M; Olivotto M; Wanke E; Becchetti A; Defilippi P; Wymore R; Arcangeli A
Mol Biol Cell; 2005 Jun; 16(6):2972-83. PubMed ID: 15800067
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers.
Duranti C; Iorio J; Lottini T; Lastraioli E; Crescioli S; Bagni G; Lulli M; Capitani C; Bouazzi R; Stefanini M; Carraresi L; Iamele L; De Jonge H; Arcangeli A
Mol Cancer Ther; 2021 Aug; 20(8):1338-1349. PubMed ID: 34045227
[TBL] [Abstract][Full Text] [Related]
7. VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome.
Pillozzi S; Brizzi MF; Bernabei PA; Bartolozzi B; Caporale R; Basile V; Boddi V; Pegoraro L; Becchetti A; Arcangeli A
Blood; 2007 Aug; 110(4):1238-50. PubMed ID: 17420287
[TBL] [Abstract][Full Text] [Related]
8. Targeting the hERG1 and β1 integrin complex for cancer treatment.
Arcangeli A; Iorio J; Duranti C
Expert Opin Ther Targets; 2024 Mar; 28(3):145-157. PubMed ID: 38372580
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Pillozzi S; Masselli M; De Lorenzo E; Accordi B; Cilia E; Crociani O; Amedei A; Veltroni M; D'Amico M; Basso G; Becchetti A; Campana D; Arcangeli A
Blood; 2011 Jan; 117(3):902-14. PubMed ID: 21048156
[TBL] [Abstract][Full Text] [Related]
10. The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells.
Fortunato A
Cell Oncol (Dordr); 2017 Aug; 40(4):367-378. PubMed ID: 28593575
[TBL] [Abstract][Full Text] [Related]
11. Optical methods in the study of protein-protein interactions.
Masi A; Cicchi R; Carloni A; Pavone FS; Arcangeli A
Adv Exp Med Biol; 2010; 674():33-42. PubMed ID: 20549938
[TBL] [Abstract][Full Text] [Related]
12. Long-term channel block is required to inhibit cellular transformation by human ether-à-go-go-related gene (hERG1) potassium channels.
Pier DM; Shehatou GS; Giblett S; Pullar CE; Trezise DJ; Pritchard CA; Challiss RA; Mitcheson JS
Mol Pharmacol; 2014 Aug; 86(2):211-21. PubMed ID: 24830940
[TBL] [Abstract][Full Text] [Related]
13. Role of HERG1 potassium channel in both malignant transformation and disease progression in head and neck carcinomas.
Menéndez ST; Rodrigo JP; Alvarez-Teijeiro S; Villaronga MÁ; Allonca E; Vallina A; Astudillo A; Barros F; Suárez C; García-Pedrero JM
Mod Pathol; 2012 Aug; 25(8):1069-78. PubMed ID: 22460808
[TBL] [Abstract][Full Text] [Related]
14. Physical and functional interaction between integrins and hERG potassium channels.
Arcangeli A; Becchetti A; Cherubini A; Crociani O; Defilippi P; Guasti L; Hofmann G; Pillozzi S; Olivotto M; Wanke E
Biochem Soc Trans; 2004 Nov; 32(Pt 5):826-7. PubMed ID: 15494025
[TBL] [Abstract][Full Text] [Related]
15. The integrin beta1 subunit transmembrane domain regulates phosphatidylinositol 3-kinase-dependent tyrosine phosphorylation of Crk-associated substrate.
Armulik A; Velling T; Johansson S
Mol Biol Cell; 2004 Jun; 15(6):2558-67. PubMed ID: 15034138
[TBL] [Abstract][Full Text] [Related]
16. Clarithromycin inhibits autophagy in colorectal cancer by regulating the hERG1 potassium channel interaction with PI3K.
Petroni G; Bagni G; Iorio J; Duranti C; Lottini T; Stefanini M; Kragol G; Becchetti A; Arcangeli A
Cell Death Dis; 2020 Mar; 11(3):161. PubMed ID: 32123164
[TBL] [Abstract][Full Text] [Related]
17. Cooperative subunit interactions mediate fast C-type inactivation of hERG1 K+ channels.
Wu W; Gardner A; Sanguinetti MC
J Physiol; 2014 Oct; 592(20):4465-80. PubMed ID: 25063820
[TBL] [Abstract][Full Text] [Related]
18. C-Linker Accounts for Differential Sensitivity of ERG1 and ERG2 K+ Channels to RPR260243-Induced Slow Deactivation.
Gardner A; Sanguinetti MC
Mol Pharmacol; 2015 Jul; 88(1):19-28. PubMed ID: 25888115
[TBL] [Abstract][Full Text] [Related]
19. Human ether-a-go-go-related gene K+ channels regulate shedding of leukemia cell-derived microvesicles.
Zheng F; Li J; Du W; Wang N; Li H; Huang S
Leuk Lymphoma; 2012 Aug; 53(8):1592-8. PubMed ID: 22292854
[TBL] [Abstract][Full Text] [Related]
20. Molecular Basis of Altered hERG1 Channel Gating Induced by Ginsenoside Rg3.
Gardner A; Wu W; Thomson S; Zangerl-Plessl EM; Stary-Weinzinger A; Sanguinetti MC
Mol Pharmacol; 2017 Oct; 92(4):437-450. PubMed ID: 28705808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
